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Novel bisnaphthalimidopropyl (BNIPs) derivatives
as anticancer compounds targeting DNA in human
breast cancer cells†
Maria Kopsida,a Gemma A. Barron,a,b Giovanna Bermano,b Paul Kong Thoo Lina and
Marie Goua*a
Bisnaphthalimidopropyl (BNIP) derivatives are a family of compounds that exert anti-cancer activities
in vitro and, according to previous studies, variations in the linker sequence have increased their DNA
binding and cytotoxic activities. By modifying the linker sequence of bisnaphthalimidopropyl
diaminodicyclohexylmethane (BNIPDaCHM), a previously synthesised BNIP derivative with anti-cancer
properties, three novel BNIP derivatives were designed. Bisnaphthalimidopropyl-piperidylpropane
(BNIPPiProp), a structural isomer of BNIPDaCHM, bisnaphthalimidopropyl ethylenedipiperidine dihydro-
bromide (BNIPPiEth), an isoform of BNIPDaCHM with a shorter linker chain, and (trans(trans))-bisnaphtha-
limidopropyl diaminodicyclohexylmethane (trans,trans-BNIPDaCHM), a stereoisomer of BNIPDaCHM,
were successfully synthesised (72.3–29.5% yield) and characterised by nuclear magnetic resonance spec-
troscopy (NMR) and mass spectrometry (MS). Competitive displacement of ethidium bromide (EtBr) and
UV binding studies were used to study the interactions of BNIP derivatives with Calf Thymus DNA. The
cytotoxicity of these derivatives was assessed against human breast cancer MDA-MB-231 and SKBR-3
cells by MTT assay. Propidium iodide (PI) ﬂow cytometry was conducted in order to evaluate the cellular
DNA content in both breast cancer cell lines before and after treatment with BNIPs. The results showed
that all novel BNIPs exhibit strong DNA binding properties in vitro, and strong cytotoxicity, with IC50
values in the range of 0.2–3.3 µM after 24 hours drug treatment. Two of the novel BNIP derivatives,
BNIPPiEth and trans,trans-BNIPDaCHM, exhibited greater cytotoxicity against the two breast cancer cell
lines studied, compared to BNIPDaCHM. By synthesising enantiopures and reducing the length of the
linker sequence, the cytotoxicity of the BNIP derivatives was signiﬁcantly improved compared to
BNIPDaCHM, while maintaining DNA binding and bis-intercalating properties. In addition, cell cycle
studies indicated that trans,trans-BNIPDaCHM, the most cytotoxic BNIP derivative, induced sub-G1 cell
cycle arrest, indicative of apoptotic cell death. Based on these ﬁndings, further investigation is under way
to assess the potential eﬃcacy of trans,trans-BNIPDaCHM and BNIPPiEth in treating human breast
cancer.
Introduction
Breast cancer is the most commonly occurring cancer in
women, with incidence rates approaching 1.38 million cases
per year worldwide.1 Breast cancer, depending on whether it
develops in response to the hormone oestrogen, is divided in
two categories: oestrogen dependent (ER+) and oestrogen inde-
pendent (ER−) cancer.2 ER+ breast cancers respond better to
anti-oestrogen (endocrine) therapies, such as tamoxifen and
exemestane, by inhibiting the eﬀect of oestrogen and decreas-
ing the uncontrolled proliferation of breast cancer cells.2 On
the other hand, ER-breast cancers are more invasive and less
responsive to current standard-of-care treatment regimes, such
as fluorouracil, epirubicin and doxorubicin, which do not
selectively target breast cancer cells hence leading to severe
side eﬀects.3 Over the last few decades, there have been
numerous attempts to develop novel breast cancer-specific
therapies that will act on specific molecular targets, increasing
selectivity and potentially reducing treatment resistance and
side eﬀects.4 DNA was one of the first biochemical targets
identified in anti-cancer therapeutics,5–7 which lead to a new
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generation of agents with improved eﬃcacy and solubility.
In the 1990s naphthalimido compounds, such as mitonafide,
were found for the first time to be highly active against cervical
cancer and leukaemia cells, however, a Phase I clinical trial
revealed that mitonafide treatment at doses above 118 mg m−2
× 5 days lead to central nervous system toxicity.8 Subsequently,
bisnaphthalimido compounds were synthesised with improved
therapeutic properties. They had also overcome the dose-limit-
ing toxicity issues,9 however, their aqueous insolubility limited
their potential use as anti-cancer agents.10 Kong Thoo Lin and
Pavlov10 designed and synthesised a number of bisnaphthal-
imidopropyl derivatives, by incorporating natural polyamines
and, diamino or triamino alkyl chains into the bisnaphthal-
imide structure. This led to improved aqueous solubility, as
well as anti-cancer activity.11,12 Additional alterations to the
linker were performed to confirm that BNIP moiety was crucial
for in vitro anti-cancer activity. One such alteration was the
introduction of a bicyclohexylmethane group (in the linker
chain). This tended to reduce the flexibility of the linker but it
enhanced its DNA binding properties, resulting in the syn-
thesis of BNIPDaCHM (Fig. 1). BNIPDaCHM contained a
pseudo-asymmetrical centre with a mixture of three isomers
(cis,cis; trans,trans and cis,trans) (indicated by asterisks,
Fig. 1).13,14 This linker chain modification resulted in a more
cytotoxic BNIP derivative against triple negative breast cancer
cells MDA-MB-231 (IC50 value 6.8 µM), compared to chemo-
therapy drug doxorubicin (IC50 value 14.4 µM), after 24 hours
treatment.13 With regards to selectivity, non-tumourigenic
breast epithelial MCF-10A cells were found to be less respon-
sive to BNIPDaCHM (IC50 value 6.06 µM) than doxorubicin.
13
In the present work, we describe for the first time, the syn-
thesis and characterisation of three novel BNIP derivatives that
were designed by considering several modifications to the
structure of BNIPDaCHM (Fig. 1). The first BNIP derivative,
bisnaphthalimidopropyl-piperidylpropane dihydrobromide
(BNIPPiProp) is a structural isomer of BNIPDaCHM that con-
sists of only one species (enantiopure). The aim of synthesis-
ing BNIPPiProp was to investigate whether cytotoxicity and
DNA binding properties diﬀer among structural isomers and
how the position of the ring structure in the linker chain
aﬀects cytotoxicity. The second BNIP derivative, bisnaphthal-
imidopropyl-ethylenedipiperidine (BNIPPiEth), consists of one
carbon less between the two piperidine ring structures, com-
pared to BNIPPiProp and was synthesised in order to assess
the eﬀect of a shorter linker chain on cytotoxicity and DNA
binding properties. In parallel, it is still unknown whether the
cytotoxicity of BNIPDaCHM is associated with the existence of
the three isomers in its structure, therefore (trans(trans))-4,4′-
methylenebis (cyclohexylamine), the only commercially avail-
able stereoisomer precursor required to synthesise trans,trans-
BNIPDaCHM the latter being, the third BNIP derivative used
in this study. The synthesis of trans,trans-BNIPDaCHM lead to
the investigation into the importance of this stereoisomer
compared to the mixture of three stereoisomers present in
BNIPDaCHM in relation to DNA binding aﬃnities, cytotoxicity
in MDA-MB-231 and SKBR-3 breast cancer cell lines and the
possible mode of cell death via cell cycle analysis were studied
for the three novel compounds. By using two cell lines which
are unresponsive to currently available anti-cancer regimes, it
is possible to extend our knowledge on BNIP derivative cyto-
toxicity against diﬀerent breast cancer cells types and to gain
more information about their mode of action.
Results and discussion
Chemical synthesis
The synthesis of bisnaphthalimidopropyl-dipiperidyl-propane
and ethane free bases was carried out by reacting 1,3-bis-(4-
piperidyl) propane or 1,3-bis-(4-piperidyl)ethane and
toluenesulfonyloxypropylnaphthalimide in tetrahydrofuran
(THF) under reflux with subsequent addition of cesium car-
Fig. 1 Chemical structure of BNIP derivatives: BNIPDaCHM with its
three stereo isomers, bisnaphthalimidopropyl-piperidylpropane
(BNIPPiProp), bisnaphthalimidopropyl-ethylenedipiperidine (BNIPPiEth)
and (trans(trans))-4,4’-methylenebis(cyclohexylamine) (trans,trans-
BNIPDaCHM).
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bonate (Scheme 1). The corresponding BNIPPiProp and
BNIPPiEth dihydro chloride and bromide salts were prepared
by their treatment with HBr/g·CH3CO2H and conc. HCl (72.3%
and 29.5% yield), respectively.
The synthetic strategy of trans,trans-BNIPDaCHM
(Scheme 2) was based on methods previously developed in our
group for the synthesis of BNIPDaCHM.13 Here the single
isomer trans,trans-4,4′-methylenebiscyclohexylamine was used
as the starting material. The synthesis of trans,trans-N4,N4-
dimesityl-dicyclohexylmethane was carried out by reacting
trans,trans-4,4′-methylenebis(cyclohexylamine), with 2-mesity-
lenesulfonyl chloride (Mts-Cl) in anhydrous pyridine (21.1%
yield). N-Alkylation was performed by reacting trans,trans-N4,N4-
dimesityl-dicyclohexylmethane with toluenesulfonyloxypropyl-
naphthalimide in DMF (37.0% yield). For the final step,
trans,trans-bisnaphthalimido-dimesityl-dicyclohexylmethane
was dissolved in DCM, followed by treatment with hydro-
bromic acid/glacial acetic acid (HBr/g·CH3CO2H). All new com-
pounds were fully characterised by NMR and high resolution
mass spectrometry (see Experimental section). The melting
point of trans,trans-BNIPDaCHM was found to be 120–125 °C
indicating good purity. In contrast, BNIPDaCHM exhibited a
higher melting point range (105–130 °C) compared to trans,
trans-BNIPDaCHM. BNIPPiProp and BNIPPiEth had melting
points in the range of 160–170 °C and 120–125 °C, respectively,
indicating their high purity.
According to matched molecular pair (MMP) analysis,
which has been broadly used in the last few years to investigate
the eﬀects of hydrogen bond donors/acceptors and rotatable
bonds on the melting point of drug-like compounds,15–17 has
shown that an increase in rotatable bonds leads to a decrease
of the melting point.18 Therefore, the existence of the three
isomers on BNIPDaCHM increases its flexibility and leads to a
low melting point, compared to the three novel compounds.
On the other hand, BNIPPiProp, with the longest linker
sequence, has the highest melting point (160–170 °C), due to
the increase of hydrogen bond donors/acceptors that stabilize
the crystal lattice.18
DNA binding studies
Competitive displacement of ethidium bromide from Calf
Thymus DNA. Competitive displacement of ethidium bromide
(EtBr) with BNIPs from Calf Thymus DNA was carried out to
investigate their DNA interactions. EtBr is a well known DNA
structural probe and intercalating dye that exerts fluorescence
once it binds to DNA.19 A compound with higher DNA binding
aﬃnity than EtBr either displaces EtBr or breaks the DNA sec-
ondary structure, resulting in fluorescence quenching and a
decrease in fluorescence intensity.20 All three novel BNIP
derivatives competitively displaced EtBr from Calf Thymus DNA
duplexes. For each derivative, a range of concentrations
Scheme 1 Synthetic pathway of bisnaphthalimidopropyl-piperidylpro-
pane (BNIPPiProp) and bisnaphthalimidopropyl-ethylenedipiperidine
dihydrobromide (BNIPPiEth).
Scheme 2 Synthetic pathway of (trans(trans))-4,4’-methylenebis(cyclo-
hexylamine) (trans,trans-BNIPDaCHM).
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(0–7 µM) were tested and the corresponding IC50 values calcu-
lated. All BNIP derivatives displaced EtBr with IC50 values
ranging from 1.1 to 5.6 µM confirming their high DNA
binding aﬃnity (Table 1). BNIPDaCHM was included in the
following studies in order to evaluate and compare its binding
properties to the novel BNIP derivatives.
The order of their binding aﬃnity to Calf Thymus DNA from
highest to lowest was BNIPPiEth (1.1 ± 0.2 µM), BNIPDaCHM
(2.3 ± 0.1 µM), BNIPPiProp (3.9 ± 0.3 µM) and trans,trans-
BNIPDaCHM (5.6 ± 0.2 µM).
BNIPPiEth, which has the shortest linker with two piper-
idine rings attached to an ethyl group, had the lowest IC50
value. The shorter length of the linker chain, as well as the
incorporation of a nitrogen atom within the cyclohexane ring,
compared to BNIPDaCHM, resulted in increased DNA binding.
On the other hand, the incorporation of the nitrogen atom
within the cyclohexane ring was not found to improve the
binding properties of BNIPPiProp (3.9 ± 0.3 µM), compared to
BNIPDaCHM and BNIPPiEth, confirming that the length of
the bridging alkyl linkers is crucial and aﬀects significantly
BNIP binding to DNA duplexes.21
The trans,trans-BNIPDaCHM, a stereoisomer of
BNIPDaCHM, gave a IC50 value of 5.6 ± 0.2 µM. BNIPDaCHM,
which consists of three isomers, gave a IC50 value of 2.3 ±
0.1 µM, which indicated that in absence of cis,cis or/and cis,
trans, trans,trans-BNIPDaCHM was not able to achieve as high
DNA-binding interactions as BNIPDaCHM. Based on the above
results, the planar structure of BNIPDaCHM and its mixture of
three isomers was found to improve its interacting properties
within the DNA base pairs, compared to trans,trans-
BNIPDaCHM. This was confirmed since trans,trans-
BNIPDaCHM resulted in a lower IC50 value compared to
BNIPDaCHM, revealing that each of the three or more than one
(trans,trans/cis,trans or trans,trans/cis,cis) isomers co-existing in
BNIPDaCHM, are involved in the intramolecular complexes/
interactions with DNA. By isolating one of its isomers (trans,
trans-BNIPDaCHM), the DNA binding aﬃnity was decreased
(p < 0.01). The planar structure of BNIPDaCHM allows it to fit
between the base pairs and in parallel, its rotational freedom
within the plane of the aromatic rings, may allow the exposure
of more than one intercalating sidechain to DNA.22
UV binding studies
The binding of the novel BNIP derivatives with Calf Thymus
DNA was also studied by UV spectroscopy. A continuous
decrease in UV absorption was observed at 260 nm, within the
range of drug concentrations (0–7 µM) investigated. The appar-
ent binding constants for the compounds under study, were
calculated from the intercept and the slope by plotting
A0/(A − A0) against BNIP derivative concentrations,23 where
A0 and A correspond to the absorbance values in the absence
and presence of each BNIP compound (Fig. 2a), respectively.
Binding constant values K for the BNIP derivatives range
between 3.25 × 104–12.23 × 104 (Fig. 2b), and indicate that
all BNIP derivatives interact with the DNA helix. The
highest binding constant was observed with BNIPDaCHM
(12.23 × 104), followed by trans,trans-BNIPDaCHM (11.38 × 104)
and BNIPPiEth (10.85 × 104). The lowest K binding constant
was observed for BNIPPiProp (3.25 × 104). This outcome is in
agreement with the competitive displacement of EtBr studies
(Table 1), highlighting the importance of linker chain length
in achieving strong DNA binding interactions. In addition, the
UV absorption studies revealed that trans,trans-BNIPDaCHM,
the less eﬀective derivative in displacing EtBr from DNA,
obtained a high binding constant (11.38 × 104), compared to
BNIPDaCHM (12.23 × 104: highest K binding constant). This
suggests that trans,trans-BNIPDaCHM exhibits lower inter-
Fig. 2 (a) Competitive displacement of EtBr from Calf Thymus DNA.
Plot of A0/(A − A0) versus 1/CBNIP of the interaction between BNIP
derivatives and Calf Thymus DNA. (b) K constant values of BNIPP deriva-
tives after UV binding studies.
Table 1 Competitive displacement of EtBr from Calf Thymus DNA.
Eﬀect of diﬀerent BNIP concentrations (0–7 µM) on % ﬂuorescence
intensity compared to Calf Thymus DNA alone. IC50 value: concen-
tration of each BNIP derivative required to cause a 50% decrease on
ﬂuorescence intensity of DNA-EtBr complex. Data are the mean ± SD of
three independent experiments (n = 3). *P < 0.05, **P < 0.01, compared
to BNIPDaCHM
BNIP derivatives Mean ± SD IC50 value (µM)
Calf Thymus DNA alone –
BNIPDaCHM 2.3 ± 0.1
BNIPPiProp 3.9 ± 0.3*
BNIPPiEth 1.1 ± 0.2*
trans,trans-BNIPDaCHM 5.6 ± 0.2**
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calation capacity than the other two isomers present in the
BNIPDaCHM. However, the trans,trans isomer has similar DNA
aﬃnity to the mixture of isomers present in BNIPDaCHM as
demonstrated by their binding constant (Fig. 2b). Previous
molecular modelling studies have revealed that for the most
stable conformation of bis-1,8-naphthalimide in presence of
DNA, the naphthalimide rings obtain an antiparallel orien-
tation and are detected in the major groove.24 Furthermore,
they have been reported to induce strand cleavage, allowing
the electron transfer and formation of hydrogen bonding
between the nitrogen atoms and the nucleobases (excluding
guanine) of the minor groove,25 suggesting that the high
K binding constant of trans,trans-BNIPDaCHM is obtained not
only via intercalation, but also via binding on the major and
minor groove of DNA.
Biological studies
Cytotoxicity. Cytotoxicity evaluation of BNIPDaCHM,
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM was
performed by using MTT assay26 against MDA-MB-231 and
SKBR-3 cells (Table 2). After 24 hours treatment, all novel BNIP
derivatives, exhibited strong cytotoxicity with IC50 values
ranging from 1.4 μM to 3.3 μM in MDA-MB-231 cells (Table 2),
compared to previously synthesised BNIPs or DNA intercalat-
ing drugs (doxorubicin) that have been tested against the same
cell line, with IC50 values ranging from 4.9 μM to 12.7 μM.13
In particular, trans,trans-BNIPDaCHM exhibited the lowest
IC50 value of 1.4 μM, BNIPPiEth an IC50 of 1.8 μM and
BNIPPiProp an IC50 of 3.3 μM. A similar pattern of cytotoxicity
was found for SKBR-3 cells, although the IC50 values were
between 0.2–0.7 μM (Table 2).
trans,trans-BNIPDaCHM (1.4 μM) was more active (p < 0.01)
than BNIPDaCHM (2.3 μM) against MDA-MB-231 cells,
showing that the existence of a single isomer in the linker
sequence results in a more cytotoxic compound, compared to
a compound which contains a mixture of isomers. BNIPPiEth
was more cytotoxic (p < 0.05) than BNIPDaCHM, suggesting
that the shorter length of the linker chain, as well as the incor-
poration of the nitrogen atom within the cyclohexane ring, not
only improved the binding properties of BNIPPiEth, but
enhanced significantly its in vitro cytotoxicity, too. Regarding
BNIPPiProp, the derivative with the longest linker sequence
and the highest IC50 value, it was found that the length of the
linker chain length plays an important role in the functionality
and eﬀectiveness of a BNIP derivative. In addition, all the
derivatives followed a similar pattern of cytotoxicity in both
cell lines however, they appeared more cytotoxic against
SKBR-3 cells. This may be due to the diﬀerent mutational and
tumorigenic statuses.
MDA-MB-231 cells are triple negative breast cancer cells
(TNBC) (oestrogen receptor negative (ER−), progesterone recep-
tor negative (PR−), human epidermal growth factor receptor
2 negative HER2−) with four gene mutations being reported
(BRAF, CDKN2A, KRAS and TP53) and a fast-growing basal B
tumour classification (49.5% proliferation rate),27 which
makes them less responsive to anti-cancer treatments, such as
docetaxel or carboplatin, compared to cells that are hormone
receptor positive.27 On the other hand, SKBR-3 cells are double
negative breast cancer cells (DNBC) (ER−, PR−, HER2+) without
gene mutations and with a luminal tumour classification
(35.2% proliferation rate),27 resulting in a better response to
anti-cancer treatments compared to TNBCs, which is in agree-
ment with our findings.
Cell cycle analysis
Cell cycle distribution of MDA-MB-231 and SKBR-3 cells after
cell synchronisation was studied using flow cytometry follow-
ing PI staining28 with the most active compound trans,trans-
BNIPDaCHM (Table 2), together with BNIPDaCHM (mixture of
isomers) that has been reported to induce cell cycle
instability.29
An increase in the proportion of MDA-MB-231 cells in sub-
G1 phase (122.3%, 139.3% and 142.2% increase, respectively)
was exhibited relative to the control, whilst in G1 phase, the
cell population was decreased after treatment with
BNIPDaCHM (1 µM) and trans,trans-BNIPDaCHM (1 µM)
(31.3% and 29.4% decrease, both p < 0.05) (Fig. 3a). The above
results indicate that both BNIPDaCHM and trans,trans-
BNIPDaCHM induced sub-G1 cell cycle arrest to a greater
extent than camptothecin. Camptothecin is a well known posi-
tive control for sub-G1 arrest30,31 and for inducing
apoptosis.32,33
Therefore, this suggests that BNIPDaCHM and trans,trans-
BNIPDaCHM could use similar mechanisms of action com-
pared to camptothecin and may trigger apoptotic cell death in
MDA-MB-231 and SKBR-3 human breast cancer cells.
Similar experiments were carried out with synchronised
SKBR-3 cells (Fig. 3b), where the cell population was signifi-
cantly increased in sub-G1 phase only after treatment with
BNIPDaCHM (136.4%) and camptothecin (210.2%), but not for
trans,trans-BNIPDaCHM, demonstrating that the eﬀect of the
two BNIP derivatives was diﬀerent in each cell line and that
the existence of one isomer has a diﬀerent eﬀect on cell cycle
distribution. Therefore, it is suggested that the mechanisms of
cell death among trans,trans-BNIPDaCHM and BNIPDaCHM
may diﬀer, even though they belong to the same family of
compounds.
Table 2 Cytotoxicity of BNIP derivatives against MDA-MB-231 and
SKBR-3 cells. MDA-MB-231 and SKBR-3 cells were treated with diﬀerent
BNIP concentrations (0–10 μM) for 24 hours at 37 °C. IC50 values corres-
pond to the concentration required to reduce cell growth by 50% com-
pared to control cells. Data presented as mean ± SEM of 3 independent
experiments (n = 3). *P < 0.05, **P < 0.01, compared to BNIPDaCHM
BNIP derivatives
IC50 values (µM)(Mean ± SEM)
MDA-MB-231 SKBR-3
BNIPDaCHM 2.3 ± 0.1 0.4 ± 0.1
BNIPPiProp 3.3 ± 0.1** 0.7 ± 0.1*
BNIPPiEth 1.8 ± 0.1* 0.3 ± 0.1*
trans,trans-BNIPDaCHM 1.4 ± 0.1** 0.2 ± 0.0*
Paper Organic & Biomolecular Chemistry
9784 | Org. Biomol. Chem., 2016, 14, 9780–9789 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
Se
pt
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
1/
10
/2
01
6 
12
:1
7:
48
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Conclusions
In this study, we have shown that three BNIP derivatives,
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM could
have potential as anti-cancer agents. DNA binding aﬃnity was
confirmed as each BNIP derivative had the ability to competi-
tively displace EtBr from DNA and quenched UV absorption in
presence of DNA in a dose dependent manner. Linker
sequence modifications showed stronger cytotoxic eﬀects
against MDA-MB-231 and SKBR-3 cells, compared to the par-
ental compound BNIPDaCHM. In addition, cell cycle analysis
showed that trans,trans-BNIPDaCHM induced sub-G1 arrest in
MDA-MB-231 cells, but not in SKBR-3 cells, suggesting that its
mode of action could be cell line dependent, in contrast to
BNIPDaCHM that shows a similar trend in cell cycle arrest in
both cell lines. This study has confirmed that BNIPPiProp,
BNIPPiEth and trans,trans-BNIPDaCHM have the ability to
interact with DNA, intercalate and stabilise the double helix,
and exhibit better cytotoxic activities, compared to previously
synthesised BNIP derivatives. Further research is ongoing into
the mode of DNA damage, cell death or pathway deregulations
in human breast cancer cell lines.
Experimental
Chemical synthesis
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM were syn-
thesised according to the methods (with some modifications)
previously described by Kong Thoo Lin and Pavlov.10 The
chemical structure, purity and stability of the derivatives were
confirmed by TLC, NMR, MS and melting point determi-
nation. All reagents were purchased from Fisher Scientific or
Sigma-Aldrich, unless otherwise stated. TLC was performed on
silica gel 60 F254 aluminium plates (EMD/Merck) in chloro-
form/methanol (95 : 5). NMR was recorded on a Bruker 400
Ultrashield spectrometer operating at 400.1 MHz for 1H and
100.6 MHz for 13C. Accurate mass spectra were obtained by
were obtained on Thermo Scientific LTQ Orbitrap XL or
Waters Xevo G2-S analytical instruments (EPSRC National
Mass Spectrometry Service Centre at Swansea University,
Swansea).
Synthesis of bisnaphthalimidopropyl-dipiperidyl-propane base
1,3-Bis-(4-piperidyl)propane (1.19 × 10−3 mol, 0.25 g) and
toluenesulfonyloxypropylnaphtalamide (2.39 × 10−3 mol,
0.98 g) were dissolved in tetrahydrofuran (THF) (6 mL). Using
a reflux condenser, the reaction was stirred at 50 °C for
15 minutes and after the addition of caesium carbonate (3.069
× 10−3 mol, 1 g), the reaction was left to stir overnight at 50 °C.
The reaction was monitored with TLC and once complete, the
solution was poured into icy water (100 mL). A precipitate was
formed and after vacuum filtration, the product was dried in a
vacuum oven at 45 °C overnight. The crude product (base of
BNIPPiProp) was recrystallized from ethanol and the pure
product was characterised by 1H-NMR (64.8% yield).
1H-NMR (CDCl3): δH 8.53–8.51 (2H, CH aromatic protons),
8.14–8.12 (2H, CH aromatic protons), 7.70–7.66 (2H, CH aro-
matic protons), 4.17–4.14 (2, CH2 protons), 2.84–2.82 (2H, CH2
protons), 2.41–2.37 (2H, CH2 protons), 1.91–1.83 (2H, CH2
protons), 1.79–1.74 (2H, CH2 protons), 1.51–1.48 (2H, CH2
protons), 1.71–1.09 (H, CH proton) ppm (parts per million).
Synthesis of BNIPPiProp salt
The base of BNIPPiProp (1.459 × 10−3 mol, 1 g) was dissolved
in DCM (20 mL) and HBr/CH3CO2H (2 mL) was added slowly.
The reaction was stirred for 2 hours at room temperature and
reaction completion was monitored by TLC yielding a preci-
pitate. The precipitate was filtered by vacuum filtration and
washed with DCM (30 mL) and ether (10 mL). The BNIPPiProp
salt was dried under negative pressure in a vacuum oven set at
45 °C for 2 hours (72.3% yield).
1H-NMR (CDCl3): δH 8.53–8.51 (2H, CH aromatic protons),
8.14–8.12 (2H, CH aromatic protons), 7.70–7.66 (2H, CH aro-
matic protons), 4.69 (2H, CH2 protons), 4.17–4.14 (2H, CH2
protons), 2.84–2.82 (2H, CH2 protons), 2.41–2.37 (2H, CH2
Fig. 3 Cell cycle distribution of MDA-MB-231 and SKBR-3 cells after
BNIP treatment. (a) Quantiﬁcation of MDA-MB-231 and (b) SKBR-3 cell
cycle proﬁles by ﬂow cytometry following PI staining after 24 hours
treatment with BNIPDaCHM, trans,trans-BNIPDaCHM and camptothe-
cin. DMSO/dH2O (50% v/v) was used as the solvent control. The percen-
tage of the cell population in sub-G1, G1, S and G2/M were calculated
from histograms of linear FL-2 plots in the ungated regions (10 000
events). Data are mean ± SEM of three independent experiments (n = 3),
conducted in duplicates. *P < 0.05, compared to solvent control.
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protons), 1.91–1.83 (2H, CH2 protons), 1.79–1.74 (2H, CH2
protons), 1.51–1.48 (2H, CH2 protons), 1.71–1.09 (H, CH
proton) ppm.
13C-NMR (CDCl3): δH 164.24 (CvO), 131.87 (CH aromatic),
131.60 (C aromatic), 131.24 (CH aromatic), 127.75 (C aro-
matic), 126.94 (CH aromatic), 122.80 (C aromatic), 56.58 (CH2),
54.03 (CH2), 39.10 (CH2 aromatic), 36.77–35.69 (CH), 32.34
(CH2), 25.33 (CH2) and 23.76 (CH2) ppm.
Mass spectrum (HRMS), m/z = 685.3739 (M + H)+
C43H48N4O4 requires 685.3748 (M + H)
+.
Synthesis of 4,4-ethylenedipiperidine
4,4-Ethylenedipiperidine dihydrochloride (7.428 × 10−4 mol,
0.2 g) was dissolved in distilled water (2 mL), sodium hydrox-
ide (2 M, 1 mL) was added, which resulted in the formation of
a precipitate. The pH was 14. The resulting was transferred
into a separating funnel (100 mL) followed by extraction with
DCM (300 mL). The organic layer was collected, dried with
sodium sulfate and filtered. The solvent was evaporated by a
rotary film evaporator. The final white solid product was left to
dry under negative pressure in a vacuum oven at 45 °C for
30 minutes (90.6% yield). The synthesis of the free base was
confirmed by 1H-NMR.
1H-NMR (CDCl3): δ 2.98–2.95 (2H, CH2 protons), 2.52–2.45
(2H, CH2 protons), 1.8 (NH), 1.60–1.57 (2H, CH2 protons),
1.25–1.21 (H, CH protons) and 1.19–1.16 (2H, CH2 protons)
ppm.
Synthesis of BNIPPiEth base
4,4-Ethylenedipiperidine (5.044 × 10−4 mol, 0.1 g) was reacted
with toluenesulfonyloxypropyl-naphthalamide (1.001 × 10−3
mol, 0.41 g, 2.01 excess). Caesium carbonate (3.069 × 10−3
mol, 1 g) was added in the reaction. All the reagents were dis-
solved in THF (6 mL) and the solution refluxed overnight at
60 °C. The reaction was monitored using TLC. Once the reac-
tion was complete, the solution was poured into icy water
(100 mL), which resulting in the formation of a precipitate.
The precipitate was filtered using a Buchner funnel and the
product was left to dry under negative pressure in a vacuum
oven at 45 °C for 60 minutes (72.3% yield). The crude product
was recrystallised from ethanol and the pure product was
characterised by 1H-NMR.
1H-NMR (CDCl3): δH 8.52–8.50 (2H, CH aromatic protons),
8.13–8.11 (2H, CH aromatic protons), 7.69–7.65 (2H, CH aro-
matic protons), 4.18–4.14 (2H, CH2 protons), 2.83–2.80 (2H,
CH2 protons), 2.40–2.36 (2H, CH2 protons), 1.90–1.83 (2H, CH2
protons), 1.79–1.71 (2H, CH2 protons), 1.48 (2H, CH2 protons),
1.2 (H, CH protons) and 1.00–0.80 (2H, CH2 protons) ppm.
Synthesis of BNIPPiEth
BNIPPiEth (0.1 g) was dissolved in DCM (20 mL). Then, conc.
HCl (1.5 mL) was added dropwise and the solution stirred at
room temperature for 60 minutes, which resulted in the for-
mation of a pale, blue precipitate. The latter was filtered and
washed with ether (50 mL) and afterwards with ethanol
(50 mL). The product was left under negative pressure in a
vacuum oven at 45 °C for 60 minutes (29.5% yield).
1H-NMR (CDCl3): δH 8.42–8.38 (2H, CH aromatic protons),
7.82–7.78 (2H, CH aromatic protons), 4.05–4.01 (2H, CH2
protons), 2.7 (2H, CH2 protons), 2.44–2.43 (2H, CH2 protons),
2.05 (2H, CH2 protons), 1.70–1.67 (2H, CH2 protons), 1.35–1.32
(H, CH protons) and 1.090 (2H, CH2 protons) ppm.
13C-NMR (CDCl3): δH 164.10 (CvO), 134.81 (CH aromatic),
131.76 (C aromatic), 131.18 (CH aromatic), 127.92 (C aro-
matic), 127.68 (CH aromatic), 122.59 (C aromatic), 55.40 (CH2),
52.27 (CH2), 37.79 (CH), 29.43 (CH2) 23.04 (CH2) and 22.54
(CH2) ppm.
Mass spectrum (HRMS), m/z = 671.5372 (M + H)+
C42H46N4O4 requires 671.3592 (M + H)
+.
Synthesis of N-(3-hydroxypropyl)naphthalimide
1,8-Naphthalic anhydride (0.050 mol, 10 g) was dissolved in di-
methylformamide (DMF) (140 mL). Once the 1,8-naphthalic
anhydride was totally dissolved, 3-amino-1-propanol
(0.050 mol, 3.75 g) and 1,8-diazabicylo[5.4.0]undec-7-ene
(DBU) (13 mL) were added. The reaction was left to stir for
5 hours at 85 °C. Reaction completion was monitored with
TLC and once completed; the solution was poured into icy
water (200 mL) while stirring with a glass rod to form a precipi-
tate. The precipitate was filtered and washed with water. The
pure product was characterised using 1H-NMR. Yield was cal-
culated as: 53.9%.
1H-NMR (CDCl3): δH 8.66–8.63 (2H, aromatic H, doublet, J =
7.2 Hz), 8.29–8.25 (2H, aromatic H, doublet, J = 8.4 Hz),
7.83–7.78 (2H, aromatic H, doublet, J = 8.0 Hz), 4.41–4.38 (3H,
triplet, J = 5.6 Hz), 3.64–3.59 (2H, CH2, multiplet) 3.23 (OH,
singlet) and 2.06–2.00 (2H, CH2 multiplet) ppm.
Synthesis of toluenesulfonyloxypropylnaphthalimide
N-(3-Hydropropyl)naphthalimide (0.0196 mol, 5.0 g) was dis-
solved in anhydrous pyridine (70 mL), whilst stirring on ice.
Once the N-(3-hydroxypropyl)naphthalimide was completely
dissolved, p-toluenesulfonyl chloride (Ts-Cl) (0.0394 mol,
7.51 g, 2.01 excess) was slowly added to the reaction. The reac-
tion was left at 4 °C overnight. The reaction was monitored
using TLC and once it was complete, the solution was poured
into icy water (200 mL) to form a precipitate which was filtered
and washed thoroughly with water. The crude product was
recrystallised from ethanol (68.2% yield).
1H-NMR (CDCl3): δH 8.59–8.57 (2H, aromatic H, doublet,
8.2 Hz), 8.25–8.23 (2H, aromatic H, triplet, 7.2 Hz), 7.81–7.76
(2H, multiplet), 7.30 (2H, aromatic H, doublet, 1.2 Hz),
4.27–4.20 (2H, CH2, multiplet), 2.44 (3H, CH3, singlet) and
2.19–2.12 (2H, CH2, multiplet) ppm.
Synthesis of N4,N4-dimesityl-dicyclohexylmethane
4,4′-Methylenebis(cyclohexylamine) (4.75 × 10−3 mol, 1.0 g)
was dissolved in anhydrous pyridine (10 mL) and left to stir for
15 minutes. 2-Mesitylenesulfonyl chloride (Mts-Cl) (9.56 ×
10–3 mol; 2.1 g) was added. The reaction was left to stir over-
night at room temperature and TLC confirmed completion of
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reaction. The solution was poured into icy water (150 mL) with
the formation of a precipitate. The latter was filtered by
vacuum filtration, left to dry in a vacuum oven set at 45 °C for
24 hours (43.3% yield).
1H-NMR (CDCl3): δH 7.30 (NH), 6.97 (4H, CH aromatic
protons), 2.99 (4H, CH protons), 2.67–2.66 (6H, CH3-Mts
protons) and 1.73–1.49 (CH2 and cyclohexane protons) ppm.
Synthesis of protected bisnaphthalimido-dimesityl-
dicyclohexylmethane
N4,N4-Dimesityl-dicyclohexylmethane (6.968 × 10−4 mol, 0.4 g)
and toluenesulfonyloxypropylnaphthalimide (1.400 × 10−3
mol, 2.01 excess) were dissolved in DMF (8 mL). Afterwards,
excess of caesium carbonate (1.13 g, 3.5 × 10−3 mol, 2.5 g
excess) was added slowly. The reaction was left to stir for
48 hours at 60 °C. After TLC confirmed the reaction was com-
plete, the solution was poured into icy water (150 mL) to form
a precipitate. After vacuum filtration and several washes with
water, the product was left to dry under negative filtration in a
vacuum oven at 45 °C for 3 hours (92.2% yield). The product
was recrystallised from ethanol and characterised by NMR.
1H-NMR (CDCl3): δH 8.50–8.47 (2H, aromatic H), 8.18–8.15
(2H, aromatic H), 7.72–7.67 (2H, aromatic H), 6.87 (2H,
CH-Mts H), 6.55–6.53 (2H, CH-Mts H), 3.94–3.92 (2H, CH2),
3.12–3.10 (2H, CH2), 2.87–2.80 (2H, CH2), 2.35–2.32 (3H, CH3),
2.05–2.04 (3H, CH3), 1.61–1.58 (H, CH), 1.61 (2H, CH2)
1.49–1.37 (2H, CH) and 1.04 (2H, CH2) ppm.
13C-NMR (CDCl3): δH 163.87–162.76 (CvO), 134.36 (C aro-
matic), 131.40–130.74 (C aromatic), 127.75 (C aromatic), 35.75
(CH2), 30.41 (CH2), 21.97 (CH3) and 20.32 (CH3) ppm.
Synthesis of bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt
Bisnaphthalimido-dimesityl-dicyclohexylmethane (3.813 × 10−4
mol, 0.4 g) was dissolved in dichloromethane (DCM) (8 mL).
Afterwards, hydrobromic acid/glacial acetic acid (HBr/
CH3CO2H) (1 mL) was added drop wise. The reaction was
stirred overnight at room temperature. TLC was used to
confirm that the reaction was complete. The precipitate
formed, was filtered by vacuum filtration and washed with
DCM (15 mL) and ether (5 mL). The final product was dried
under negative pressure in a vacuum oven set at 45 °C for
3 hours (37.5% yield).
1H-NMR (CDCl3): δH 8.32–8.25 (2H, aromatic Hs), 7.73–7.65
(2H, aromatic Hs), 3.70–3.64 (2H, CH2 protons), 3.13 (2H, CH2
protons), 2.90–2.30 (3H, CH3 protons), 2.09–2.02 (3H, CH3
protons), 1.83–1.80 (H, CH proton), 1.43–1.33 (2H, CH2
protons) ppm.
13C-NMR(CDCl3): δ 163.87–162.76 (CvO), 134.36 (C aro-
matic), 131.40–130.74 (C aromatic), 127.75 (C aromatic), 35.75
(CH2) and 30.41 (CH2) ppm.
Mass spectrum (HRMS), m/z = 685.3764 (M + H)+
C43H48N4O4 requires 685.3748 (M + H)
+.
Synthesis of trans,trans-N4,N4-dimesityl-dicyclohexylmethane
trans,trans-4,4′-Methylenebis(cyclohexylamine) (2.38 × 10−4
mol, 0.05 g) was added in anhydrous pyridine (1.5 mL) and left
to stir for 15 minutes with warming. After dissolution, 2-mesi-
tylenesulfonyl chloride (Mts) (4.76 × 10−4 mol; 0.10 g) was
added. The reaction was left to stir overnight at room tempera-
ture and TLC confirmed reaction completion. The solution
was poured into icy water (10 mL) and stirred with a glass rod
until the formation of a precipitate. The suspension was cen-
trifuged and was washed 3 times with distilled water and the
precipitate was left to dry under negative pressure in a vacuum
oven set at 45 °C for overnight (21% yield). The product was
afterwards characterised by 1H-NMR.
1H-NMR (CDCl3): δH 7.31 (NH), 6.98 (4H, CH aromatic
protons), 3.87 (4H, CH protons), 2.67 (6H, CH3-Mts protons),
2.33 (3H, CH3-Mts protons), 1.84–1.82 (CH2-cyclohexane ring),
1.65–1.62 (CH2-cyclohexane ring), 1.16–1.10 (CH-cyclohexane
ring) and 0.99–0.95 (CH2 cyclohexane protons) ppm.
Synthesis of protected trans,trans-bisnaphthalimidopropyl-
dimesityl-dicyclohexylmethane
trans,trans-N4,N4-Dimesityl-dicyclohexylmethane (6.44 × 10−5
mol, 0.037 g) and toluenesulfonyloxypropylnaphthalimide
(1.29 × 10−4 mol, 0.053 g, 2.01 excess) were dissolved in DMF
(1 mL). Afterwards, excess of caesium carbonate (n = 3.07 ×
10−4 mol, 0.1 g, 5.0 excess) was added slowly. The reaction was
left to stir for 48 hours at 60 °C. After TLC confirmed the reac-
tion was complete, the solution was poured into icy water
(10 mL) to form a precipitate. The suspension was centrifuged
and was washed twice with distilled water. The product was
left to dry under negative pressure in a vacuum oven at 45 °C
for 24 hours. The crude product (59 mg, 88% yield) was puri-
fied using column chromatography and the final product
(25 mg, 37% yield) was characterised by 1H-NMR.
1H-NMR (CDCl3): δH 8.65–8.59 (2H, CH aromatic protons),
8.30–8.25 (2H, CH aromatic protons), 7.84–7.78 (2H, CH aro-
matic protons), 6.65 (4H, CH-Mts protons), 4.41–4.38 (2H,
CH2 protons), 4.06–4.04 (2H, CH2 protons), 3.71–3.68 (2H, CH2
protons), 2.68 (3H, CH3 protons), 2.46–2.44 (3H, CH3 protons),
2.34 (H, CH protons), 2.16–2.15 (2H, CH2 protons) 1.84 (2H,
CH protons) and 1.73–1.71 (2H, CH2 protons) ppm.
13C-NMR (CDCl3): δH 141.93 (CvO), 138.76 (C aromatic),
135.17 (C aromatic), 131.95 (C aromatic), 43.72 (CH2),
33.93–31.99 (CH2), 23.02 (CH3) and 20.97 (CH3) ppm.
Synthesis of trans,trans-bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt
trans,trans-Bisnaphthalimido-dimesityl-dicyclohexylmethane
(2.38 × 10−5 mol, 25 mg) was dissolved in dichloromethane
(DCM) (1.0 mL). Afterwards, hydrobromic acid/glacial acetic
acid (HBr/CH3CO2H) (0.2 mL) was added slowly. The reaction
was stirred overnight at room temperature. TLC was used to
confirm that the reaction was complete. The suspension
formed was transferred to Eppendorf tubes and centrifuged,
was with DCM (1.0 mL) and ether (1.0 mL). The final product
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was dried under negative pressure in a vacuum oven set at
45 °C for 3 hours to give the product as a white solid (8.3 mg,
41% yield).
1H-NMR (CDCl3): δ 8.53–8.49 (2H, CH aromatic protons),
4.16–4.12 (2H, CH aromatic protons), 3.42 (2H, CH aromatic
protons) 3.04 (2H, CH2 protons), 2.94 (2H, CH2 protons),
2.51–2.49 (3H, CH3 protons), 2.09–1.99 (3H, CH3 protons),
1.75–1.72 (H, CH proton), 1.31–1.28 (2H, CH2 protons) ppm.
13C-NMR(CDCl3): δ 164.26 (CvO), 131.82–131.23 (C aro-
matic), 127.99–127.75 (C aromatic), 122.66 (C aromatic), 42.45
(CH2) and 40.61–37.61 (CH2) ppm.
Mass spectrum (HRMS), m/z = 685.3732 (M + H)+
C43H48N4O4 requires 685.3748 (M + H)
+.
Ethidium bromide (EtBr) fluorescence displacement studies
BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM working solutions (100 µM) were prepared from
stock solutions (10 mM in 50% DMSO/H20) and were further
diluted to a final concentration of 50 µM in 0.01 M saline
sodium citrate (SSC) buﬀer. Calf Thymus DNA (0.5 g) was dis-
solved in 0.01 M SSC buﬀer (100 mL). EtBr solution (200 µM)
was prepared by dissolving 3.94 mg of EtBr in distilled water
(50 mL) and was further diluted in 0.01 SSC buﬀer to give the
final concentration of 20 µM. Test solutions were prepared by
adding varying volumes of SSC buﬀer, Calf Thymus DNA solu-
tion, EtBr solution and BNIP derivative solution. The final
solutions were thoroughly mixed and analysed at 510 nm (exci-
tation) and 520 nm (emission) using a Shimadzu RF-5301
spectrophotometer. The IC50 values were determined as the
concentration (µM) required to decrease the fluorescence of
DNA bound EtBr by 50%.
UV binding studies
BNIPDaCHM, BNIPPiProp, BNIPPiEth and BNIPDaCHM
working solutions (100 µM) were prepared from their stock
solutions (10 mM) as before, and were further diluted to
20 µM final concentration in 0.01 M SSC buﬀer. Calf Thymus
DNA and 0.01 SSC buﬀer were prepared as described before
(EtBr Fluorescence Displacement studies). Test solutions were
prepared by adding Calf Thymus DNA solution (1 mL) in a
quartz cuvette and BNIP derivative solution (100 µL) was
added. The final solutions were thoroughly mixed and ana-
lysed at 260 nm using an Agilent 8453 UV-visible spectrophoto-
meter. The values of apparent binding constants (K) were cal-
culated from the intercept and slope by plotting A0/(A − A0)
against the BNIP derivative concentrations, where A0 and A
correspond to the absorbance values in absence and presence
of a compound.
Cell culture maintenance
MDA-MB-231 (ECACC, Public Health England, UK, 92020424)
and SKBR-3 (ATCC, HTB-30) cells were maintained in Roswell
Park Memorial Institute 1640 medium (RPMI-1640) (contain-
ing GlutaMAX-1 with 25 mM HEPES), supplemented with 10%
(v/v) Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin
(10 000 µg mL−1). Cells were grown at 37 °C (5% CO2).
Cytotoxicity
Colourimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
dium bromide (MTT) assay was performed to access the
growth/inhibitory eﬀects of each BNIP compound.
MDA-MB-231 and SKBR-3 cells (7.5 × 103 cells per 100 μL) were
treated with diﬀerent concentrations (0–10 μM) of BNIP deriva-
tives. After 24 hours treatment, sterile-filtered MTT solution
(1 mg mL−1) was added to each well. After 4 hours incubation
at 37 °C, the MTT solution was removed and formazan crystals
solubilised in DMSO. The plates were shaken for 20 minutes at
room temperature and absorbance measured at 560 nm
(Synergy/HT, BIOTEK, UK). For each compound, three inde-
pendent experiments were carried out and each treatment con-
sisted of six replicates per plate. Curves were used to represent
the percentage growth inhibition of MDA-MB-231 and SKBR-3
cells treated with BNIP derivatives, compared to DMSO/H2O
control that represented 100% cell viability. IC50 values were
defined as the drug concentration that reduces absorbance
compared to control values by 50%.
Cell cycle analysis
MDA-MB-231 and SKBR-3 cells (1 × 106 cells per T75 flask)
cells were washed with PBS and serum free medium added in
the flasks in order to achieve cell synchrony. The cells were
incubated in serum free medium for 24 hours. BNIP deriva-
tives (IC25 concentrations) were added and incubated for
24 hours, at 37 °C. After 24 hours treatment, the medium was
removed and collected. The cells were washed twice with PBS.
Both washes were collected and the cells trypsinised, mixed
with the collected washes and centrifuged at 2500 rpm for
5 minutes at 4 °C. The supernatant of each sample was dis-
carded, the pellet was resuspended in PBS (1 mL) and centri-
fuged at 2500 rpm for 5 minutes at 4 °C, the supernatant was
discarded and the pellet resuspended in PBS (100 µL). Then,
70% (v/v) ice-cold ethanol (900 µL) was added and samples
incubated for 2 hours at −20 °C. The cells were centrifuged at
5000 rpm for 5 minutes at 4 °C, the supernatant was discarded
and the pellet resuspended in PBS (1 mL), followed by re-
centrifugation at 5000 rpm for 5 minutes at 4 °C. The super-
natant was discarded once more and the pellet resuspended in
PBS (500 µL) and DNA extraction buﬀer (0.2 M Na2HPO4, 4 mM
citric acid, pH 7.8, 500 µL) and incubated for 5 minutes at
room temperature. The extracts were centrifuged at 5000 rpm
for 5 minutes at 4 °C, the supernatant was removed and the
pellets were resuspended in DNA staining solution (0.2 mg mL−1
Ribonuclease A (DNAse-free) and 20 µg mL−1 propidium
iodide (PI) in PBS). The samples were incubated for
30 minutes at 4 °C in the dark and PI nuclei were examined by
flow cytometry (EXPO32 ADC XL 4 color, Beckman Coulter,
UK). For cell cycle analysis, EXPO32 ADC analysis software
(Beckman Coulter, UK) was used to record and analyse 10 000
single events. The percentage of cells with DNA content in
sub-G1, G1, S and G2/M phases was calculated from histograms
of linear FL-2 plots (575 nm) in the gated region.
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Statistics
Three independent experiments were conducted and each
experiment was comprised of at least two internal replicates.
Data are presented as mean ± SD or mean ± SEM. Statistical
analysis was performed by using an unpaired Student’s t-test.
Statistically significant data were detailed when P < 0.05).
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